key: cord-0766261-5ymdgtir authors: Hayn, Manuel; Hirschenberger, Maximilian; Koepke, Lennart; Nchioua, Rayhane; Straub, Jan Hendrik; Klute, Susanne; Hunszinger, Victoria; Zech, Fabian; Bozzo, Caterina Prelli; Aftab, Wasim; Christensen, Maria Hønholt; Conzelmann, Carina; Müller, Janis Alexander; Badarinarayan, Smitha Srinivasachar; Stürzel, Christina Martina; Forne, Ignasi; Stenger, Steffen; Conzelmann, Karl-Klaus; Münch, Jan; Schmidt, Florian Ingo; Sauter, Daniel; Imhof, Axel; Kirchhoff, Frank; Johannes Sparrer, Konstantin Maria title: Systematic Functional Analysis of SARS-CoV-2 Proteins Uncovers Viral Innate Immune Antagonists and Remaining Vulnerabilities date: 2021-04-27 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109126 sha: 33e837fe50eb7a0f5eb58033f3acc76e99882b4e doc_id: 766261 cord_uid: 5ymdgtir SARS-CoV-2 evades most innate immune responses, but may still be vulnerable to some. Here, we systematically analyzed the impact of SARS-CoV-2 proteins on interferon (IFN) responses and autophagy. We show that SARS-CoV-2 proteins synergize to counteract antiviral immune responses. For example, Nsp14 targets the type I IFN receptor for lysosomal degradation, ORF3a prevents fusion of autophagosomes and lysosomes, and ORF7a interferes with autophagosome acidification. Most activities are evolutionarily conserved. However, SARS-CoV-2 Nsp15 antagonizes IFN signaling less efficiently than the orthologues of closely-related RaTG13-CoV and SARS-CoV-1. Overall, SARS-CoV-2 proteins counteract autophagy and type I IFN more efficiently than type II or III IFN signaling and infection experiments confirmed potent inhibition by IFN-γ and -λ1. Our results define the repertoire and selected mechanisms of SARS-CoV-2 innate immune antagonists, but also reveal vulnerability to type II and III IFN that may help to develop safe and effective anti-viral approaches. Our analyses revealed that several SARS-CoV-2 proteins synergize to antagonize innate immune 272 activation pathways, albeit with different efficiencies. Consequently, we determined whether IFN-α2, 273 IFN-β, IFN-γ and IFN-λ1 inhibit SARS-CoV-2 with different efficiencies ( Figure 6A and B, Figure S6A 274 and B). Treatment with type I IFN-α2 was least efficient. In contrast, at the same concentration type II 275 IFN-γ (500 U/mL) reduced viral RNA in the supernatant almost 300-fold more efficiently. At low 276 concentrations (5 U/mL) the type II and III IFNs were most active against SARS-CoV-2, which was 277 confirmed by TCID 50 analysis of the infectious particles released ( Figure 6A , B). All agents caused little if 278 any cytotoxic effects (Figure S6C ). The average remaining pathway activity of IFN-γ and IFN-λ1 279 signaling in the presence of SARS-CoV-2 proteins was 82% and 89%, respectively, compared to type I 280 IFN signaling with a remaining pathway activity 22% for IFN-α2 and 47% for IFN-β ( Figure 1C ). We 281 found a significant inverse correlation (r = 0.89) between the average remaining activity of the respective 282 signaling pathway in the presence of all SARS-CoV-2 proteins tested ( Figure 1C ) and IFN susceptibility 283 at 5 U/mL ( Figure 6C ). Autophagic turnover was strongly repressed by at least four SARS-CoV-2 284 proteins ( Figure 1D , 3B). Thus, we would expect that modulation of autophagy only weakly affects 285 SARS-CoV-2 replication. Indeed, treatment with Rapamycin, which induces autophagy, reduced viral 286 replication moderately to a maximum of 4-6-fold ( Figure S6D , E). Bafilomycin A1, which blocks 287 autophagy, had little if any effects (Figure S6E ). Both drugs were used at non-toxic concentrations 288 (Figure S6F) . 289 In conclusion, our results indicate that the overall efficiency of SARS-CoV-2 proteins in counteracting 290 specific signaling pathways correlates with the overall antiviral potency of the types of IFNs. 291 To minimize detrimental pro-inflammatory effects of IFNs in therapeutic approaches, doses required for 293 efficient viral restriction need to be reduced. Thus, we analyzed the impact of the most potent IFNs, IFN-γ 294 J o u r n a l P r e -p r o o f and IFN-λ1 and combinations thereof on SARS-CoV-2 replication in Calu-3 cells. To mimic prophylactic 295 and therapeutic settings, we examined pre-treatment for 24 h before infection with SARS-CoV-2 and 296 treatment 6 h post-infection. Overall, the effects of IFN treatment were more than 10-fold stronger in the 297 prophylactic condition than in the therapeutic treatment ( Figure 6D -F, S6G, H). Pre-treatment with a 298 single dose of IFN-γ or IFN-λ1 reduced viral RNA production by 100-to 250-fold, the combinatorial 299 treatment achieved a synergistic ~1,600-fold reduction in SARS-CoV-2 RNA released by infected cells 300 ( Figure 6D ). Post-infection treatment with either IFN-γ or IFN-λ1 reduced viral RNA in the supernatant 301 by 4-to 6-fold, combination of both cytokines reduced SARS-CoV-2 RNA ~17-fold ( Figure 6D) . 302 Expression analysis of SARS-CoV-2 S and N by Western blotting confirmed the qPCR results, and equal 303 GAPDH levels exclude effects on viral replication by cytotoxicity (Figure 6E Takeuchi and Akira, 2009). Our data reveal the extent of immune manipulation SARS-CoV-2 employs. 321 We determined the major antagonists of type I IFN induction and type I, II and III signaling as well as 322 pro-inflammatory NF-κB activity encoded by SARS-CoV-2 (Nsp1, Nsp5, Nsp13, Nsp14, ORF6 and 323 ORF7b). Autophagy is majorly targeted by Nsp15, ORF3a, E, M and ORF7a. Subsequent mechanistic 324 studies revealed that SARS-CoV-2 proteins synergistically block type I IFN signaling and autophagy at 325 various levels. We reveal that Nsp14 expression induced degradation of the type I IFN receptor, IFNAR, 326 thus blocking activation of the crucial transcription factors STAT1 and STAT2. Both ORF3a and ORF7a 327 stopped autophagic degradation, but employ two different mechanisms: Whereas ORF3a prevented 328 autophagosome-lysosome fusion, ORF7a reduced the acidity of fused autophago-lysosomes. The 329 mechanism of ORF3a was confirmed in a recent report (Miao et al., 2021) . Examination of the functional 330 conservation showed that SARS-CoV-2 Nsp15 was less efficient in blocking innate immune activation, 331 both type I IFN induction and signaling, than SARS-CoV-1 Nsp15. This may ultimately cause SARS-332 CoV-2 to be better controlled by the innate immune system than SARS-CoV-1, explaining higher 333 numbers of subclinical infections and thus overall lower mortality rates of the current pandemic CoV. 334 Correlation of the remaining pathway activity of IFN/pro-inflammatory cytokine signaling cascades in the 335 presence of SARS-CoV-2 proteins revealed that type I IFN induction and signaling are strongly 336 antagonized by SARS-CoV-2 ( Figure 1C , 6C). Consequently, the virus is relatively resistant against type 337 I IFN. However, type II and III IFN signaling are overall seemingly less antagonized. In line with this, 338 treatment with IFN-γ and IFN-λ1 drastically reduced SARS-CoV-2 replication. Notably, combinatorial 339 treatment of SARS-CoV-2 with these two IFNs was synergistic. Additional induction of anti-340 inflammatory autophagy further enhanced the anti-viral effect. This may pave the way for future anti-viral 341 therapies against SARS-CoV-2 based on concerted innate immune activation. Why would multiple effective proteins target the same pathway? Our assays revealed that the targeting 353 mechanisms are not redundant and may act synergistically (Figures 1-4) . This could allow the virus to 354 tightly control the targeted pathway, thus minimizing the anti-viral effect of innate immune activation. 355 Notably, several proteins of SARS-CoV-2 involved in immune evasion including ORF6, ORF3a, ORF7a, 356 M and E accumulate at the Golgi network or in perinuclear spaces, alluding to the emerging role of the 357 Golgi as a hub for immune manipulation (Kagan, 2012; Tao et al., 2020). Future studies will hopefully 358 see more mechanistic data on SARS-CoV-2 proteins and unravel their combined role during the infection. 359 While our screening approach may pick up most counteraction strategies, we possibly miss some. For 360 example, many non-structural proteins form complexes, which are not present upon individual 361 overexpression. Expression levels of the viral proteins during an infection may impact the strength of the 362 antagonism, which will not be reflected by their individual overexpression. In addition, tagging the 363 proteins may alter their function. Finally, the virus itself may hide from recognition, not activating innate 364 immune defenses in the first place. using the most effective IFN is paramount. We show that type II and type III IFNs were most active 378 against SARS-CoV-2 at low concentrations (Figure 6 ). This is supported by recent reports (Busnadiego et release IFN-γ, whose innate immune signaling may also contribute to increased clearance of the infection. 387 Our data further indicates that treatment with multiple IFNs is synergistic ( Figure 6 ). Thus, a promising 388 anti-viral approach may be a combinatorial treatment with different types of cytokines, effectively also 389 reducing the burden of side-effects. Combined with anti-inflammatory approaches such as autophagy Heatmaps represent one example of at least two independent repeats, each consisting of three biological 440 replicates. See also Figure S1 . Table 536 and available from the Lead Contacts. sodium pyruvate, and 1x non-essential amino acids. Caco-2 (human epithelial colorectal adenocarcinoma 554 kindly provided by Prof. Barth, Ulm University) cells were maintained in DMEM containing 10% (v/v) 555 FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x 556 non-essential amino acids. Vero E6 (Cercopithecus aethiops derived epithelial kidney cells) cells were 557 maintained in DMEM supplemented with 2.5% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 558 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x non-essential amino acids. All cells were cultured at 559 37°C in a 5% CO 2 , 90% humidity atmosphere. The proximal origin of 760 SARS-CoV-2 Catalytic Function 762 Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the Middle East Respiratory 763 Auto-antibodies against type I IFNs in patients with 766 life-threatening COVID-19 SARS-CoV-2-specific T cell immunity in cases of SARS, and uninfected controls Imbalanced Host Response to SARS-CoV-2 Drives Development 772 of COVID-19 IFITM proteins promote SARS-CoV-2 infection of human lung cells Organization of the ER-Golgi interface for membrane traffic 777 control Identification of the Rabies Virus Alpha/Beta 779 Interferon Antagonist: Phosphoprotein P Interferes with Phosphorylation of Interferon Regulatory Factor 780 Antiviral activity of type i, ii, and iii interferons counterbalances ace2 inducibility and restricts 783 sars-cov-2. MBio SARS : epidemiology CUMULATIVE NUMBER OF CASES AND 785 DEATHS IN VARIOUS COUNTRIES IN Clinical and immunological features of severe and moderate coronavirus disease 2019 Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated 791 immunity article Autophagy during viral infection -A double-edged 793 sword Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and 796 correct lipid trafficking in Niemann-Pick C cells Hosts and Sources of Endemic Human 798 Advances in Virus Research An "Old" protein with a new story: Coronavirus endoribonuclease is 800 important for evading host antiviral defenses Autophagy in infection, inflammation and immunity SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel 876 subsite cooperativity The Zinc Finger Antiviral Protein restricts SARS-CoV-2 A Multidisciplinary Therapeutic Approach for Reducing the Risk of 881 Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and 882 Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Measles Virus V Protein Is a Decoy Substrate for IκB 887 Kinase α and Prevents Toll-Like Receptor 7/9-Mediated Interferon Induction Bidirectional traffic between the Golgi and the endosomes -889 machineries and regulation Type 1 891 interferons as a potential treatment against COVID-19 SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel 894 to inhibit translation Pre-existing immunity to SARS-CoV-2: the knowns and unknowns Interferon beta-1b for COVID-19 Papain-like protease regulates SARS-CoV-2 viral spread and 900 innate immunity SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be 903 Inhibited by Bismuth Salts Side effects of interferon-905 α therapy Intracellular detection of viral nucleic acids TRIM proteins: New players in virus-induced autophagy. PLoS 909 Pathog Measles Virus C Protein Interferes with TRIM23 mediates virus-induced autophagy via 914 activation of TBK1 Critical Role of Type III Interferon Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells Expression of SARS-CoV-2, RaTG-13-CoV and SARS-CoV-1 constructs and functional 54 comparison. A -I, Immunoblots of WCLs of HEK293T cells transiently transfected with indicated SARS-CoV-2 RaTG13-CoV or SARS-CoV-1 expression plasmids and stained with anti-V5 (A-H) and anti-actin antibodies or anti 56 J, Quantitative real-time PCR analysis of IFNB1 mRNA levels in HEK293T cells 57 expressing indicated proteins, normalized to GAPDH mRNA Vector transfected samples were set to 100%. Bars represent the mean of n=3-4±SEM (biological replicates Bars represent the mean of n=3-4±SEM (biological replicates). n.d, not 61 detectable. L, pISRE Firefly luciferase promotor induction in IFN-β stimulated HEK293T cells previously 62 transfected with the indicated amounts of NSP3 of SARS-CoV-2, RaTG13-CoV or SARS-CoV-1. Firefly luciferase 63 activities were quantified as RLU/s and normalized to cell metabolic activity (CellTiter Glo); stimulated vector 64 control was set to 100%. FLAG-tagged MeV V was used as a control. Bars represent the mean values of n=3±SEM 65 RABV P was used as a control. Immunoblots of WCLs stained 67 with anti-V5, anti-RABV P, anti-actin. N, Comparison of IFN-β antagonism of the V5-tagged NSP15 RaTG13-CoV and SARS-CoV-1 as described in (J). FLAG-tagged MeV V was used as a control Immunoblots of WCLs stained with anti-V5, anti-FLAG, anti-actin analyzing the particles, the total area was determined. Cells treated with 1 µM chloroquine overnight were 630 used as positive control. were treated and stained for the transfected proteins as described in the Immunofluorescence method-651 paragraph. After acquiring images of 30+ transfected cells, fluorescent puncta in the cells were counted. 652Here, puncta displaying both eGFP and mCherry fluorescence (non-acidified autophagosomes) and 653 puncta displaying only mCherry fluorescence (acidified autophagosomes) were counted separately. The 654 J o u r n a l P r e -p r o o f sum of both was calculated for the total number of autophagosomes per cell. Cells treated with 100 nM 655Bafilomycin A1 for 8 h were used as positive control. 656 657 RT-qPCR. SARS-CoV-2 N (nucleoprotein) transcript levels were determined as previously 658 described (Bozzo et al., 2020; Nchioua et al., 2020) . In brief, supernatants were collected from SARS-659CoV-2 infected Calu-3 cells 48 h post-infection. Total RNA was isolated using the Viral RNA Mini Kit 660 according to the manufacturer's instructions. RT-qPCR was performed as previously described using 661 Raw data was analyzed using R. Outliers (below 0.05 and above 0.95) appearing in more than 2 cases 727 were removed as artefacts of the overexpression. Heatmaps were generated using R, using the inbuilt 728 • Numerous SARS-CoV-2 proteins synergize to suppress immune sensing and signaling 11• Nsp14 targets IFNAR1 for lysosomal degradation 12• ORF3a and ORF7a block autophagy by different mechanisms 13• Synergistic treatment with IFN-γ and -λ1 is highly effective against SARS-CoV-2 14